Drugs / Molixan
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT04780672 Comparator | Mar 2021 → May 2022 | COVID-19 | Pharma VAM | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Molixan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04780672 ↗ |
| Route | Intramuscular | “The investigational drug in this study is Molixan in the dosage form of 30 mg/ml solution for intravenous and intramuscular injection.” NCT04780672 ↗ |
| Route | Intravenous | “The investigational drug in this study is Molixan in the dosage form of 30 mg/ml solution for intravenous and intramuscular injection.” NCT04780672 ↗ |